OVERVIEW
Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

POSTER SESSION
Posters will be displayed in Ryman Exhibit Hall. Each session is for one day:

1. Set Up
- 7:00am-8:15am. All posters must be up by 8:15am.

2. Open
- Ryman Exhibit Hall will be open from: 7:00am - 5:00pm, Monday and Tuesday, and 7:00am -1:30pm Wednesday.

   All food functions (continental breakfasts, breaks and lunches) as well as exhibits will be located in Ryman Exhibit Hall.

3. Discussion Time
- Presenters should be at their poster between 12:15-1:15pm to discuss their posters with interested viewers.

4. Take Down
- All posters must be taken down by 6:00 pm on Monday and Tuesday; posters must be taken down by 2:00pm on Wednesday.

NOTE: Neither ISPE or the Opryland Resort & Convention Center will be responsible for any poster that is left up overnight or is lost or damaged.

NUMBERING SYSTEM
Each poster board will be numbered. The poster number is the first number listed. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the final program, which will be available at the registration desk. Please note the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the final program and the special issue of Pharmacoepidemiology and Drug Safety, is in brackets [xxx] after the title of the abstract.

POSTER SPECIFICATIONS
1. Posters must be designed to fit a space 4 feet high by 8 feet wide. Vertical posters will not fit the boards; only horizontal posters are allowed. The board will be the only support device available. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board. Poster orientation: Landscape.

2. Posters may be attached to the boards by pushpins or male Velcro. Please bring your own mounting supplies.
Mary Jo V Pugh, B Graeme Fincke, Arlene Bierman, Francesca Cunningham, Dan R Berlowitz. (United States)

31 Pregnancy Registries: Streamlining Regulatory Requirements To Increase Enrollment [31]
Susan S Roberts, Deborah L Covington, Peggy A Doi. (United States)

32 Is Spontaneous Adverse Event Reporting Stimulated by DTCA? Experience from a Low-Dose Oral Contraceptive [32]
Sonal S Shah, Ana Aymes, Georgia Lehnert, Robyn Jones, Patrick Caubel. (United States)

33 Utilisation Patterns of Over-the-Counter Emergency Contraception [33]
Sinikka Silho, Heidi Oksama, Kirsi Pietila, Elina Hemminki. (Finland)

34 Who, Where, and What in Spontaneous Reports [34]
Kristina Star, Marie Lindquist. (Sweden)

35 Predictive Value of a Computerized Signal Detection Algorithm (MGPS) When Applied to FDA AERS Database [35]
Manfred Hauben, Louisa Walsh, Lester Reich. (United States)

36 A Retrospective Analysis of Morbidity Associated with Coded Postoperative Ileus among Open Laparotomy Bowel Surgery Patients [36]
Rachel E Williams, Timothy J Bell, Peter Wang, William B Saunders. (United States)

37 Post-Licensure Safety Surveillance for Recombinant Human Coagulation Factor VIIa [37]
Jennifer J Wood, Kathyna A O’Connell, Robert P Wise. (United States)

38 Cognitive Impairment Associated with H2 Receptor Antagonists in a Community-Based Sample of Elderly African Americans [38]
Hisham S Aljadhey, Michael D Murray, Kathleen A Lane, Sujuan Gao, Kathleen S Hall, Hugh Hendrie. (United States)

39 Medications and Pregnancy: A Population-Based Study [39]
Anick Béard, Élodie Ramos, Lucie Blais, Djamal Berbiche. (Canada)

40 Interim Results from a Modified Event Monitoring Study of Travoprost as Used in Primary Care in England [40]
Andrew J Boshier, Lynda V Wilton, Saad AW Shakir. (United Kingdom)

41 Prevalence and Factors Associated with the Off-label Use of Antipsychotic, Antidepressant and Anticonvulsant Medications among Georgia Medicaid Eligibles in 2001 [41]
Hua Chen, Bradley C Martin. (United States)

42 Use of Propensity Scores To Identify Possible Medication Dispensing Errors among Patients with Alzheimer’s Disease [42]
J Alexander Cole, Shao Zhu, Leo J Russo, Daniel Fife, Alexander M Walker. (United States)

43 Use of Beta-Blockers and Risk of Hip and Vertebral Fracture: Relationships to Daily and Cumulative Dose [43]
Frank De Vries, Patrick C Souverein, Marie L De Bruin, Hubert GM Leufkens, Cyrus Cooper, Tjeerd P Van Staa. (Netherlands)

44 Risk of Clinical Fractures after Gonadotropin-Releasing Hormone (GnRH) Agonist Therapy for Non-Metastatic Prostate Cancer [44]
Matthew R Smith, Simone Peart Boyce, Erick Moyneur, Mei Sheng Duh, Monika K Raut, Jane Bradman, Jennifer C Sung. (United States)

45 Incidence of Selected Outcomes among Matched Cohorts of Initiators of Racemic Zopiclone, Temazepam, and Zolpidem in the General Practice Research Database [45]
P Mona Eng, Najat Ziyadeh, Beth L Nordstrom, Judy Caron, David Amato, John D Seeger. (United States)

46 Cancer Risk among Danish Women with Silicone Breast Implants [46]
Soren Friis, Lisbet R Hølmich, Joseph K McLaughlin, Jon P Fryzek, Trine Henriksen, Jørgen H Olsen. (Denmark)

47 Epidemiology and Treatment Patterns of Psoriasis in the General Practice Research Database (GPRD) [47]
Joel M Gelfand, Xingmei Wang, Qing Liu, Andrea Neiman, Rachel Weinstein, David J Margolis, Andrea B Saunders. (United States)

48 The Association between p.r.n. (As-Needed) Medication and Aggressive Incidents in Psychiatric Inpatients [48]
Laurette E Goodhard, Joost J Stolker, Eibert R Heerdink, Henk LI Nijman, Toine CG Egberts. (Netherlands)

49 Evaluation of an Automated Risk Score for Determining the Risk for NSAID-Related Gastrointestinal Events Using Pharmacy Data [49]
Maarten J ten Berg, Wim G Goettsch, Peter AGM de Smet, Ron MC Herings. (Netherlands)

50 Effectiveness of Antipsychotic Treatments in a Nation-Wide Cohort of 2230 Patients in Community Care after the First Hospitalization Due to Schizophrenia and Schizoaffective Disorder [50]
Jari K Hautka, Jari Tiihonen, Timo Klaauka, Kristian Wahlbeck, Jouko Lonnqvist. (Finland)

51 Retrospective Cohort Study on Relationship between Short-Term Fever of Unexplained Origin and Tiaonbaokang or Purun Injection(Puerarin Injection) [51]
Xue-rong Huang, Rong-yuan Zheng, Xi-jia Wang, Xiu-hua Zhang, Rong Jin. (China)

52 Analgesic Use in Early Pregnancy [52]
Michele L Jonsson Funk, Katherine E Hartmann. (United States)

53 Who’s Watching the Safety of OTC Drugs—and How? [53]
Lynn Rosenberg, David W Kaufman, Allen A Mitchell. (United States)

54 Case-Control Study on the Association of Upper Gastrointestinal Bleeding and Non-Steroidal Anti-Inflammatory Drugs in Japan [54]
Kiyoshi Kubota, Tsugumichi Sato, Akira Terano, Kento Moro, Chistu Sakamoto, Shinichi Ota, Susana Perez-Gutthann, David W Kaufman. (Japan)

55 Impact of Exception Drug Status on the Appropriate Use of TZDs [55]
Marc Doraus, Jacques LeLorier. (Canada)

56 Do Statins Induce Higher Risk of Myopathy in Patients with Hyperlipidemia [56]
M-E Shi Lin, Nen-Chung Chang, Yen-Hui Chen, Yea-huei Kao Yang. (Taiwan)

57 Safety Profile of Tacrolimus Ointment as Used in General Practice in England: Interim Results of an Ongoing Prescription-Event Monitoring Study [57]
Vanessa Marshall, Lynda V Wilton, Saad AW Shakir. (United Kingdom)

58 New Users of Inhaled Corticosteroids (ICS) in the United Kingdom Have Higher Probability of Continuous Use Than New Users in the Netherlands [58]
Tanja T Menczekeb, Jitka Pokladnikova, Marcel L Bouvy, Svetlana V Belitser, Madelon Bracke, Jan AM Raaijmakers, Hubert GM Leufkens. (Netherlands)

59 Lymphoma Risk in Patients with Rheumatoid Arthritis Who Received 2 or More Disease Modifying Anti-Rheumatic Drugs (DMARDS): A Retrospective Cohort Study in the GPRD [59]
Daniel I Mines, Laura A Novelli, Holly Yu. (United States)
60 Temporal Relationship between Non-Steroidal Anti-Inflammatory Drugs / COX-2 Inhibitors and Cardiovascular Risk – A Retrospective Analysis Using the Veteran Affairs (VA) Database [60]
Stephen P Motsek, Karen L Rascati, Jamie C Barner, Anthony J Busti, James P Wilson, Kenneth A Lawson. (United States)

62 The WHI Publication: What Are the Changes in Pattern of HRT Use and the Persistence Rate? [62]
Marie Pascale Guay, Alice Dragomir, Yola Moride, Sylvie Perreault. (Canada)

63 Racial Differences in Medications Used in African American Compared to White Young Adults from a Population-Based Sample: The CARDIA Study [64]
Maribel Salas, O Dale Williams, Lucia Juarez, Yongin Kim, Sharina D Person, Catarina Kiefe. (United States)

64 Drugs Associated with QTc Prolongation and Torsade de Pointes [64]
Sabine MJM Straus, Miriam CJM Sturkenboom, Cornelis S Cornvan der Hofft, Jan A Kors, Albert Hofman, J Herre Kingma, Jacqueline CM Witteman, Bruno HCh Stricker. (Netherlands)

65 Safety of Drugs Prescribed during Pregnancy in Russia: A Way Far from Advised Standards [65]
Elena A Strizhenok, Leonid S Stratchounski. (Russia)

66 Case-Control Study of the Association between Use of Acid Suppression Drugs and Risk of Gastric Cancer [66]
Hani M Tamim, Andre Duranceau, Long-Qi Chen, Jacqueline CM Witteman, Bruno HCh Stricker. (Netherlands)

67 A Prospective Cohort Study of Patients with HER-2 Positive Metastatic Breast Cancer: Report of Recruitment and Data Collection Methods in the registHER Experience [67]
Marianne E Ulcickas Yood, Wei Dong, Jin Wang, James Reiman, Pavel Napalkov, Virginia Paton. (United States)

68 Non-Steroidal Anti-Inflammatory Drugs and the Risk of Ageing Macular Disease [68]
Annemieke M van Kints, Katia MC Verhamme, Shamila Boekhoorn, Miriam CJM Sturkenboom, Bruno Ch Stricker. (Netherlands)

69 Determinants of Suboptimal Antidepressant Use in the Elderly: Are Patient or Physician Factors More Important? [69]
Philip S Wang, M Alan Brookhart, Sebastian Schneeweiss, Jerry Avorn, Robert J Glynn, Amanda Patrick, Daniel H Solomon. (United States)

70 Persistence, Compliance and Adherence to Statins: A Comparison of “Treat to Target” and “Fire and Forget” Treatment Strategies [70]
Li Wei, Thomas M MacDonald, Michael J Murphy. (United Kingdom)

71 Risk of Adverse Pregnancy Outcome after Maternal Use of Fluoroquinolone [71]
Pia Wogelius, Mette Nørgaard, Mette Gislim, Henrik Carl Schönheyder, Henrik Toft Sørensen. (Denmark)

72 Testing the Feasibility of Using an Administrative Medical Claims Database To Study the Pharmacogenetics of a Rare Adverse Event [72]
Thanos I Zavras, Donnie P Funch, Jared D Danielson, Cheryl A Farello, Julian B Ar buckle, Edward L Murrelle. (United States)

73 Cost-Effectiveness of Increasing Influenza Vaccination Rate by Community Pharmacists Advocating Immunization [73]
Takashl Usami, Masayuki Hashiguchi, Tsuyoshi Kouhara, Akira Ishii, Taizou Nagata, Mayumi Mochizuki. (Japan)

74 Use of Post-Market Safety Surveillance Data To Detect Drug Interactions: Drug A and Coumadin [74]
Isaac W Hammond. (United States)

75 Methodological Aspects and Contents of the Pharmacoepidemiological Questionnaire for Children and Adolescents - KiGGs-Survey of the Robert Koch-Institute in Germany [75]
Hans-Ulrich W Melchert, Hildtraud Knopf, Ellen Pabel, Marianne Braemer-Hauth. (Germany)

76 Therapeutic Risk Management: A Case Study of Recombinant Human Erythropoietin Therapy among Renal Failure Patients [76]
Dennis J Cotter, Mae Thamer, Yi Zhang, Kevin Stefanik. (United States)

77 Redundancy: A Discrepancy between What We Want and What We Get from Our Effect Estimates [77]
Nicolle M Gatto, Ulka B Campbell. (United States)

78 Applying Multinomial Logistic Regression in Hypertensive Patients [78]
Ana P Ferreira, Jose P Guerreiro, Maria F Oliveira. (Portugal)

79 Lower and Upper Bounds on the Correlation between Treatment and Instrumental Variable Limit the Applicability of the Method [79]
Edwin P Martens, Wiebe R Pestman, Ton de Boer, Svetlana V Belitser, Olaf H Klungel. (Netherlands)

80 Differential Risks of Death for Users of Carvedioll According to the Specialty of the Prescriber [80]
Marc Dorais, Jacques LeLorier. (Canada)

81 Comparison of Three Methods in Causality Assessment: Expert Judgement, French Algorithm and Logistic Method [81]
Helene Theophile, Yannick Arimone, Francoise Haramburu, Ghada Miremont-Salame, Nicholas Moore, Annie Fourrier-Reglat, Bernard Begaud. (France)

82 ASSIGN: A Proactive Systematic Approach to Vaccine-Vigilance in the U.S. Vaccine Adverse Event Reporting System [82]
Vitali Pool, Steve P James, Robert T Chen. (United States)

83 Predictors of Heart Failure in COPD Medicaid Patients [83]
Antoine C El Khoury, Fadia T Shaya, Weir R Matthew. (United States)

84 Studying Co-Medication Patterns Using Large Databases [84]
Hilde Tobi, Adrianne Faber, Paul B van den Berg, J Wanzer Drane, Lolkje TW de Jong-van den Berg. (Netherlands)

85 Outpatient Pharmacist’s Interventions in Sultan Qaboos University Hospital, Oman [85]
Wael Al-Naeem, Aqeela Taqi, Issa Al-Rashdi, Kassim Al-Riyamy. (Oman)

86 Disease Management Programs Targeting Asthma and Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis [86]
Enkhe Badamgarav, Anacleto Gano, Jr., Suellen Cur Kendall. (United States)

87 Changes in the Utilization of Oral Antidiabetic Drugs between 1998 and 2004 in Hungary [87]
Peter Doro, Edith Kosik, Maria Matuz, Gyongyver Soos. (Hungary)

88 Pharmacoepidemiogenomics: New Paradigm in Pharmacoepidemiology [88]
Pendar Farahani, Mitchell Levine. (Canada)

89 Diabetes Mellitus Associated with Atypical Antipsychotic Use among Patients with Bipolar Disorders in a Large Managed Care Population [89]
Jeff J Guo, Paul E Keck, Jr., Hong Li, Raymond Jang, Williams Carson. (United States)
90 The Menopause Rating Scale (MRS) as Outcome Measure for Hormone Treatment [90]
Lothar AJ Heinemann, Juergen Dinger. (Germany)

91 Economic Evaluation of Sirolimus-Eluting Stents in Japan [91]
Mia Kobayashi, Shunya Ikeda. (Japan)

92 Who Are Statin Users in the Community? (A Canadian Experience) (Preliminary Report) [92]
Pendar Farahani, Kathryn Gaebel, Jacques Leloir, Sylvie Perrault, Jane Gillis, Judith Soon, Mitchell Levine. (Canada)

93 Patterns of Analgesic Use for Musculoskeletal Disorders in Rural Alberta, Canada [93]
Katherine Gooch, Cy Frank, Stuart MacLeod. (Canada)

94 Estimating Off Label Drug Use in Two Pediatric Populations Using Claims Data [94]
Susan A Oliveria, Catherine B Johannes, Teresa A Simon, William B Saunders, Paul E Stang. (United States)

95 The Cost-Effectiveness of Enhanced Depression Care to Employers [95]
Amanda R Patrick, Jerry Avorn, Francisco Azocar, Ronald Kessler, Evette Ludman, Joyce McClulloch, Gregory Simon, Philip S Wang. (United States)

96 The Norwegian Prescription Database (NorPD) - New Register for Pharmacoepidemiologic Research Covering a Whole Nation [96]
Kari Furu, Hanne Strøm, Marit Rønning, Svetlana Skurtveit, Anders Engeland, Aage Kari Furu, Hanne Strøm, Marit Rønning, Svetlana Skurtveit, Anders Engeland, Aage Tverdal. (Norway)

97 Prevalence and Treatment of Hypertensive Patients with Multiple Cardiovascular Risk Factors in Italy [97]
Miriam CJM Sturkenboom, Giampiero Mazzaglia, Gino Picelli, Essy Mozaffari, Alessandro Filippi, Claudio Cricelli. (Netherlands)

98 Duration of Therapy among Patients Dispensed Type 2 Diabetes Medications in the U.S. and U.K. [98]
Priscilla Velentgas, J Alexander Cole, Najat Ziyadeh, Laurie Costa, Kathleen Shea, John D Seeger, Alexander M Walker. (United States)

END- SESSION A

1 Patient Access to and Utilization of Prescription Drugs in the Saudi Ministry of Health Hospital Outpatient Clinics [150]
Mohamed A Alkelya, David H Kreling. (United States)

2 Contribution of Latin America to Pharmacovigilance: Analysis of the Literature [151]
Victoria E Arango, Camilo J Gonzalez, Thomas R Einarson. (Canada)

3 Increase in Prevalence of Antidepressant Use in Quebec within All Age Groups and Persons Diagnosed with Depression, Panic or Generalized Anxiety Disorders [152]
Louise Barnard. (Canada)

4 Persistence to Inhaled Corticosteroids among Asthmatic Adolescents [153]
Lucie Blais, Sylvie Perreault, Djamal Berbiche, Johanne Collin, Lyne Lalonde, Claudine Laurier. (Canada)

5 Country’s Illness Burden: Identifying New Drugs of 2004 That Could Help To Overcome It [154]
Carlos CF Vidotti, Lia LC de Castro, Simone S Calil. (Brazil)

6 Antenatal Use of Corticosteroids: Recall Accuracy in Questionnaires [155]
Maria Cederholm, Britta Alexandersson, Helle Kieler. (Sweden)

7 Use of Antiplatelet Drugs among Outpatients with Diabetes at a Medical Center in Southern Taiwan [156]
Chi Wen Chiang, Hui Fen Chiu, Hsin Lung Wu, Chun Yuh Yang. (Taiwan)

8 A Survey-Based Assessment of the Prevalence and Severity of Chronic Hand Dermatitis (ChHD) [157]
Joseph F Fowler, Mei Sheng Duh, Jane Chang, John Person, Deborah Durr, Monika Raut, Arindam Ghosh, Elana Den, Jennifer Reynolds. (United States)

9 Spontaneous Reports on Desmopressin-Associated Hyponatremia in Elderly Patients [158]
Torbjorn Callebou, Elisabet Ekman, Morten Andersen. (Denmark)

10 Abstract Withdrawn

11 Patients’ Knowledge on Generic Medications [160]
Ermelindo Fontes, José C Pimentel, Nelson Alves, Ana Paula Martins. (Portugal)

12 Illustrating Trends and Costs of Antihypertensives Using the Medical Expenditure Panel Survey, an Underused Resource in Pharmacoepidemiology [161]
Douglas Gaus, Craig Plauschinat. (United States)

13 Cornfield’s Condition Applied to Data Mining Output To Ascertain Confounding [162]
Manfred Hauben, Charles M Gerrits, Lester Reich. (United States)

14 Pituitary Apoplexy Associated with Leuprolide, Goserelin and Triptorelin [163]
Paula Gish, Carolyn A McCloskey, Mark Avigan. (United States)

15 Survey of Pharmacovigilance Programs in Latin America [164]
Juan Camilo Gonzalez R., Thomas Ray Einarson. (Colombia)

16 Adverse Events Following Influenza Vaccination in Adults 50-64 and ≥65 Years: Vaccine Adverse Event Reporting System (VAERS), 7/2002-2/10/2005 [165]
Penina Haber, Herrera Guillermo, Peng-Jun Lu, John Iskander, Kimp Walton, Frank DeStefano. (United States)

17 Beers Drugs and Medication Error Reports in North Carolina Nursing Homes [166]
Richard A Hansen, Sandra B Greene, Charlotte E Williams, Susan J Blalock, Kathleen D Crook, Roger Akers, Timothy S Carey. (United States)

18 Abstract Withdrawn[167]

19 Antihypertensive Drug Use in Diabetic Patients in Japan: A Drug Use Investigation Contrasted with Guidelines [168]
Shingo Horiguchi, Yukari Kamijima, Nobuhiro Ooba, Kyosho Kubota, Mitsunori Yagame, Shiyoure Cageyama, Kazuo Samizo, Yoshihiro Shimozono, Tadashi Kusunoki. (Japan)

20 Evaluation of Prescribing to Patients with Coronary Heart Disease Against the National Service Framework [169]
Annie Hutchison, Helen Seaman, Richard Farmer, Corinne de Vries. (United Kingdom)

21 What Happens When the Drug of Choice Is Temporarily Unavailable? A Report of a Natural Experiment in Drug Utilization in a Managed Care Setting in Israel [170]
Natan R Kahan, Dan-Andrei Waitman, David P Chinitz, Ernesto Kahan. (Israel)
<table>
<thead>
<tr>
<th>Poster Session B</th>
<th>Tuesday, August 23, 2005</th>
</tr>
</thead>
</table>

| 22 | Quality Review of Congenital Anomaly Reports Sent to the U.S. Food and Drug Administration (FDA) [171] Dianne L Kennedy, Abbie Erickson, Kathleen Uhl, Roger A Goetsch. (United States) |
| 23 | Trends in Use of Clotrimazole/Betamethasone Dipropionate Combination Products in Pediatric Patients [172] Lois La Grenade, David Moeny, Marilyn R Pitts. (United States) |
| 24 | Atypical Antipsychotic and Concomitant Psychotropic Utilization Patterns in a Schizophrenic Medicaid Population [173] Anthony M Louder, Jeff J Guo. (United States) |
| 26 | Physician Attitudes and Practice Patterns Concerning Outpatient Antibiotic Use for Older Adults [175] Joshua P Metlay, Judith Kinman, Linda Crossette. (United States) |
| 27 | Do Psychosocial Factors, Asthma Control and Quality of Life Differ between Teenagers and Adults? [176] Jocelyne Moisan, Line Guénette, Yves Bolduc, Madone Turcotte, Elileen Dorval, Jean-Pierre Grégoire. (Canada) |
| 28 | How and Why Do Men and Women Differ in Medication Usage? [177] C Ineke Neutel, Wikke Walop. (Canada) |
| 29 | Utility of Data Mining Methods in Real-World Pharmacovigilance Setting When Prospectively Compared with Traditional Signal Detection Methods [178] Vaishali K Patadia, G Scott Chandler. (United States) |
| 30 | Abstract Withdrawn [179] |
| 31 | Usage of Non-Prescription Medication by People with Diabetes in Alvaz (Khozestan State) [180] Shadi Sarahroodi, Mohammad Mehdi Nourollahi Ravari, Azadeh Ashтарjezhad, Fatemeh Jahanbakhsh Sefidi. (Islamic Republic of Iran) |
| 33 | What Influence Variation of Sale of Analgesics Containing Codeine between Regions in Norway [182] Svetlana Skurtveit, Anders Engelund, Solveig Sakshaug, Liliana Bachs, Jørgen Bramness. (Norway) |
| 34 | Variation in Antihypertensive Utilisation and Guideline Preference [183] Pieter Stoik, Boris LG Van Wijk, Eibert R Heerdink, Hubert GM Leufkens. (Netherlands) |
| 36 | Descriptive Analysis, Coded Postoperative Ileus, and Medication Utilization of Patients Undergoing Bowel Surgery Via Open Laparotomy [185] Rachel E Williams, Timothy J Bell, Peter Wang, William B Saunders. (United States) |
| 38 | How Participation in a Drug Company-Managed Clinical Trial Influenced GPs’ Guideline Adherence and Drug Preference: A Register-Based Study [187] Morten Andersen, Jakob Kragstrup, Jens Soendergaard. (Denmark) |
| 39 | Relationship between Conformity to Antidepressant Treatment Guidelines for Depressive Disorders and Cost of Health Services [188] Regis Blais, Hana Partlova, Jean Lachaine, Maïda Sewitch. (Canada) |
| 40 | The Influence of Physician Guideline Compliance on Patient Statin Adherence [189] Joanne R Campione, Betsy Sleath, Andrea K. Biddle, Morris Weinberger. (United States) |
| 41 | Utilization of Parenteral Non-Steroidal Anti-Inflammatory Drugs in the Ambulatory Service in Taiwan [190] Ching-Lan Cheng, Shih-Chen Kuo, Shu-Wen Jia, Yea-Huei Yang Kao. (Taiwan) |
| 42 | Recruiting Physicians to an Internet-Based Quality Improvement Project: Effectiveness of a Targeted, Multi-Phase, Incentive-Based Strategy [191] Jeffrey R Curtis, Angela Becker, Jeroan J Allison, Linda Casebeer, Mary Elkins, Varghese George, Catarina Kiefe, Anatachaj Panjamapirom, Ramkumar Santhanakrishnan, Claire Spettell, Norman Weissman, Andrew O Westfall, Kenneth G Saag. (United States) |
| 43 | Incidence of Peptic Ulcers during Use of Low-Dose Effervescent Calcium Carbasalate and Regular Low-Dose Acetylsalicylic Acid [192] Martijn G van Oijen, Jeannie P Dieleman, Robert Laheij, Miriam C Sturkenboom, Jan B Jansen, Freek V Verheught. (Netherlands) |
| 45 | The Trade-Off between Cardiovascular and Gastrointestinal Effects of Rofecoxib [194] Stefan R Florentinus, Eibert R Heerdink, Antonius de Boer, Liset van Dijk, Hubert GM Leufkens. (Netherlands) |
| 46 | Pneumonia in an Asthma Cohort in General Practice in the UK [195] Luis A Garcia Rodriguez, Mari-Ann Wallander, Saga Johansson, Ana Ruigomez. (Spain) |
| 47 | Is It Feasible To Conduct a Cohort Study Via the Internet? [196] Alicia Gilsenan, Patricia Tennis, Elizabeth Andrews, Xiaolei Zhou, Florence Coste, Christine Radigue. (United States) |
| 48 | Use of Rosuvastatin (Crestor®) after Introduction on to the Dutch Market [197] Myrthe PP Sukel, Wim G Goettsch, Fabian Termorshuizen, Ron MC Herings. (Netherlands) |
| 49 | Risk Factors for Inflammatory Bowel Disease in the General Population [198] Luis A Garcia Rodriguez, Antonio González-Páez, Saga Johansson, Mari-Ann Wallander. (Spain) |
51 Investigation of Deaths and Serious Illnesses Following Influenza Vaccination in a Long-Term Care Facility [200] Alison M Rue, Shauna Lyn, John K Iskander, Joel Blostein, Paul Gargiulo, Sean Shadomy, Jane Seward, Robert T Chen. (United States)

52 Comparison of the Incidence Rates of Thromboembolic Events Reported for Patients Prescribed Rofecoxib and Celecoxib in General Practice in England Using Prescription-Event Monitoring Data [201] Rachna Kasliwal, Scott Harris, Deborah Layton, Lynda Wilton, Saad Shakir. (United Kingdom)

53 Potential Limitations of Electronic Database Studies of Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs (NANSAIDs) and Risk of Myocardial Infarction (MI) [202] Leonard Iikhanoff, James D Lewis, Sean Hennessy, Jesse A Berlin, Stephen E Kimmel. (United States)


55 Association between beta-Agonists and Death in Patients with Chronic Airway Disease [204] Odile Sheehy, Jean Bourbeau, Jacques LeLorier. (Canada)

56 Health Outcomes in Women Taking Ethinylestradiol/Drosiprenone and Other Oral Contraceptives, Interim Results [205] Jeanne Loughlin, John D Seeger, P Mona Eng, C Robin Clifford, Alexander M Walker. (United States)

57 Safety Profile of Pimecrolimus Cream as Used in General Practice in England: Interim Results of an Ongoing Prescription-Event Monitoring Study [206] Vanessa Marshall, Lynda V Wilton, Saad AIW Shakir. (United Kingdom)

58 Significant Association between Previous and Future Asthma Exacerbations in Severe or Difficult-to-Treat Asthma [207] Mary K Miller, Beiyao Zheng, Howard Fox, June Lee, Sally Wenzel. (United States)

59 Cardiovascular Safety of Viagra® (Sildenafil Citrate): Results of the International Men's Health Study, a Long-Term Observational Cohort Study [208] Murray A Mittleman, Michael Lewis, Malcolm K Maclure, Gillian C Hall, Nicholas Moore, Rachel E Sobel, Robert F Reynolds, Dale B Glasser. (United States)

60 Bacteremia in Patients with Hematologic Malignancies: The Impact of Inappropriate Empirical Antibiotic Treatment on 7-Day and 30-Day Mortality [209] Mette Nørgaard, Heidi Larsson, Gitte Pedersen, Henrik C Schanheyder, Henrik T Sørensen. (Denmark)

61 Risk Factors for Peptic Ulcer Bleeding and Perforation with Celecoxib and Other Nonsteroidal Anti-Inflammatory Drugs [210] M Kay Patterson, Xiaochun Zhang, Jennifer Cutone, Jordi Castellsague, Alexander M Walker. (United States)

62 Prevalence and Predictors of Antidepressant Utilization before, during and after Pregnancy: A Population-Based Study [211] Elodie Ramos, Djamal Berbiche, Évelyne Rey, Lucie Blais, Anick Bérard. (Canada)


64 Inhaled β-Agonists and the Risk of Sudden Cardiac Death [213] Sabine MJM Straus, Miriam CJM Sturkenboom, Gysèle S Bleumink, Jeanne P Dieleman, J Herre Kingma, Johan van der Lei, Bruno HCh Stricker. (Netherlands)

65 Tranexamic Acid, Menorrhagia and Venous Thromboembolism - A Case-Control Study Using the GPRD [214] Anders Sundström, Helen Seaman, Lars Alfredsson. (Sweden)

66 Hormone Replacement Therapy and Risk of Colorectal Cancer: A Population-Based Case-Control Study [215] Mette S Tetsche, Heidi Larsson, Mette Nørgaard, Søren Friis, John A Baron, Henrik T Sørensen. (Denmark)

67 The Association between Antiepileptic Drug Use and Aplastic Anemia [216] Patricia MLA van den Bent, Patrick C Souveirein, Tjeerd P van Staa, Ron HB Meyboom, Wouter W van Solinge, Toine CG Egberts, Bert GM Leufkens. (Netherlands)

68 Fifteen Additional Months of Follow-Up Confirm the Absence of Association between Immunization with Infanrix™hexa and Sudden Unexpected Deaths [217] Thomas Verstraeten, Corinne Pierfitte, Thomas Breuer. (Belgium)

69 Trends in Cholesterol Concentrations and the Use of Statins in the Tayside Population, 1993-2002 [218] Li Wei, Thomas M MacDonald, Michael J Murphy. (United Kingdom)

70 Safety Profile of Tiotropium Used in General Practice in England: Results of a Prescription-Event Monitoring Study [219] Lynda V Wilton, Saad A Shakir. (United Kingdom)

71 Respiratory Failure in Patients with Myasthenia Gravis in the US [220] Jasminda H Wu, Mary N Haan, Wanju S Dai. (United States)

72 Longitudinal Patterns of Asthma Medication Use in Preschool Children: Results from the PIAMA-Study [221] Mira GP Zuidgeest, Henriette A Smit, Madelon Bracke, Alet Wijga, Bert Brunekeef, Hubert GM Leufkens. (Netherlands)

73 Validation of Drug Use as Proxy Identifier of Congestive Heart Failure Diagnosis [222] Annette B Beiderbeck, Maurille A Feudjo-Tepie, Samantha A St.Laurent, Nawab Qizilbash. (United Kingdom)

74 Reliability of an Adverse Drug Event Classification System for In-Hospital Pharmacovigilance [223] Kevin Haynes, Sean Hennessy, Knashawn Morales, Catherine Barnhart, Gene Gibson, Chitra Jaipaul, Darren Linkin. (United States)


76 A Method of Assigning Severity of Chronic Obstructive Pulmonary Disease Using Administrative Data [225] Suellen M Curkendall, Stephan Lanes, Cynthia de Luise, Mary Rose Stang, Earl Goehring, Jr., Dewei She, Judith K Jones. (United States)

77 Abstract Withdrawn [226]

79 Evaluation of Brighton Collaboration Standardized Case Definitions: Sensitivity, Specificity, Reliability, and Applicability for Intussusception, Fever, and Persistent Crying [228]
Katrin S Kohl, Manya Magnus, Jane Gidudu, Jonathan Li, Robert Ball, Saad B Omer, Neal Halsey, Sean Shadomy, Thomas A Farley. (United States)

80 Visual Distortions of Relative Risk and Odds Ratio in Graphical Figures Published in the Medical Literature [229]
Mitchell AH Levine, Ahmad El-Nahas. (Canada)

81 Adjusting for Physician Sampling When Calculating Reporting Rates [230]
Rita Ouellet-Hellstrom. (United States)

82 Peripheral Ischaemia and Gemcitabine - An Assessment of the Strength of Association [231]
Catharina E Raat, Andrzej Czarnecki. (Poland)

83 Different Results from Different Causal Contrasts in the Presence of Effect Modification [232]
Til Stürmer, Kenneth J Rothman, Robert J Glynn. (United States)

84 Abstract Withdrawn [233]

85 Antidiabetic Drug Treatment Patterns and Glycemic Control in a U.S. Managed Care Population [234]
Susan E Andrade, Cynthia Willey, Joseph Cohen, Jerry H Gurwitz. (United States)

Alicia Gilsenan, Elizabeth Andrews, Alki Burdett, Rebecca Martin. (United States)

87 Health Economic Analyses in South America: Analysis of the Literature [236]
Mercio Machado, Thomas R Einarson, Michael Iskedjian. (Canada)

88 Discontinuation Rates for SSRIs and Other Second-Generation Antidepressants in Outpatients with Major Depressive Disorder. A Systematic Review and Meta-Analysis [237]
Gerald Gartlehner, Rick A Hansen, Kathleen N Lohr, Bradley N Gaynes, Timothy S Carey. (United States)

89 Abstract Withdrawn [238]

90 Bullying and Medicine Use among Adolescents: Cross-Sectional Survey [239]
Bjorn E Holstein, Pernille Due, Ebba H Hansen. (Denmark)

91 Does Incorporating Medications in the Surveyors’ Interpretive Guidelines Reduce the Use of Potentially Inappropriate Medications in Nursing Homes? [240]
Kate L Lapane, Brian J Quilliam, Steve Kogut, David Dore, Carmel M Hughes. (United States)

92 Drug Expenditures among Elderly People in Belo Horizonte, Brazil [241]
Marina G Lima, Andreia Q Ribeiro, Suely Rozenfeld, Carlos H Klein, Francisco A Acurcio. (Brazil)

93 Cost-Effectiveness in the Prevention of Cerebral Infarction and Myocardial Infarction by Folic Acid Intake — Taking Genetic Screening into Account [242]
Katsunori Masaki, Koichi Miyaki, Shunya Ikeda, Kazuyuki Omae. (Japan)

94 Meta-Analysis of the Causal Relationship between Coffee Consumption and Type 2 Diabetes Mellitus [243]
Hideki Origasa, Naomi Yokoyama, Hironori Sakai, Mitsuhiko Noda. (Japan)

95 A Meta-Analysis of Randomized Controlled Trials with Paroxetine: Does Putative Mode of Action Really Improve Clinical Outcomes? [244]
Martin Katzman, Andrea C Tricco, Diane McIntosh, Marie-Josee Filteau, Pierre Bleau, Prapat Chokka, Kevin Kjemnsted, Ba’ D Pham, Hiram Mok. (Canada)

96 Local Collaborations Independently Affect the Provision of Community Pharmacy Services to Patients Performing Self-Monitoring of Blood Glucose [245]
Michiel J Storimans, Olaf H Klungel, Herre Talsma, Marcel L Bouvy, Cornelis J de Bleeuw. (Netherlands)

97 Association between Atypical Antipsychotic Drug Use and Tardive Dyskinesia Assessed by an Empirical Bayes Signal Detection Method Applied to FDA’s Adverse Event Reporting System (AERS) Database [246]
Huei-Ting Tsai, Ana Szarfman, Joseph Tonning, Jonathan G Levine, P Murali Doraiswamy. (United States)

98 Drug Consumption in the Nordic Countries between 1999 and 2003 [247]
Tinna J Voipio, Pirkko K Paakkarri, Erkki S Palva. (Finland)
11 Characteristics of End Stage Renal Disease Patients Receiving Phosphate Binder Therapy in UK Primary Care [292] Arlene M Gallagher, Heba Elgazzar, Gwenda Hughes. (United Kingdom)

12 Application of Disproportionality Analysis to Spontaneous Reports of Fluroquinolone Phototoxicity: Correlation of Reporting Rates with Drug Molecular Structure Toxicity Gradients [293] Manfred Hauben, Charles Gerrits, Lester Reich. (United States)

13 Retrospective Disproportionality Analysis on Phantom Ships (Discounted Drug-Event Associations Originally Identified through Traditional Pharmacovigilance) [294] Manfred Hauben, Lester Reich, Charles M Gerrits, Eugene P van Puijenbroek. (United States)

14 Period Prevalence of Four Autoimmune Diseases within a Large US Managed Care Population [295] Earl L Goerding, Jr., Bao-Anh Nguyen-Khoa, Ruby M Vendlø, Pavel Napalkov, Wei Dong, Judith K Jones. (United States)


18 Communication of Findings and Conclusions in Pharmacovigilance: Need for Precision [298] Manfred Hauben, Lester Reich. (United States)

19 Lifetime Co-Occurrence of Illicit Prescription Drug Use Disorders with Other Illicit Drug Use Disorders, Alcohol Use Disorders and Mental Disorders [300] Boji Huang, Deborah A Dawson D, Bridget F Grant, Frederick F Stinson FS, Patricia S Chou, Tulsji Saha, Rise B Goldstein, Sharon M Smith, June W Ruan, Roger P Pickering. (United States)

20 Identification of Adverse Events in Inpatients: Results of a Preliminary Survey in Japan [301] Shun'ya Ikeda, Mia Kobayashi, Hitoko Sakai. (Japan)


22 Prevalence of Hormone Replacement Therapy in Japan before and after the Publication of the Study Results from WHI. Japan Nurses’ Health Study [303] Tomoko Kodama, Kata Katanoda, Toshiharu Fujita, Shosuke Suzuki, Hideki Mizunuma, Takeshi Aso, Kunihiko Hayashi. (Japan)


24 Results of a Physician Survey To Evaluate Compliance with the Product Label Recommendation for Potassium Monitoring [305] Jeanne Loughlin, John D Seeger, P Mona Eng, Kelly Oh, Alexander M Walker. (United States)

25 Herbal Drug Utilization by Retired People: Results from Domiciliary Survey in Belo Horizonte/MG, Brazil [306] Luciano DP Marliere, Andreia Q Ribeiro, Maria GL Brandao, Suely Rozenfeld, Carlos H Klein, Francisco A Accuro. (Brazil)

26 Prevalence and Costs Associated with Treating Depression with Painful Physical Symptoms in a Canadian Administrative Health Services Database [307] Alki N Burdett, Charlotte C Gard, Alicia Gilsenan, Zeneat Hirji, Joel Raskin, David P Miller. (United States)


29 A Naturalistic One Year Prospective Study, Concerning Patients Suffering from Schizophrenia (DSM-IV) and Treated with Antipsychotic Drugs [310] Martin Patrick, Massol Jacques, Dalery Jean, Hardy-Bayle Marie-Christine, Gury Charles, Peretti Charles-Siegfried. (France)

30 Reliability of Information about Drug Utilization by Retired People, from Postal and Domiciliary Surveys in Belo Horizonte/MG, Brazil [311] Andreia Q Ribeiro, Cibele C Cesar, Suely Rozenfeld, Carlos H Klein, Francisco A Accuro. (Brazil)

31 Changes in the Prevalence and Incidence of Coronary Heart Disease in the UK between 1992 and 2001 [312] Helen E Seaman, Annie Hutchison, Richard DT Farmer, Corinne S de Vries. (United Kingdom)


34 Patterns of Outpatient Services and Prescription Utilization for Diabetes among Recipients with Diabetes with Versus without Comorbid Depression in a Medicaid Population [315] Murali Sundaram, Michael Smith. (United States)

35 Adverse Event Reports among the Elderly [316] Sheila R Weiss, Robert J LoCasale, Jr.. (United States)


38 Relationship between Serotonergic Antidepressants and Worsening of Parkinson’s Disease [319] Maurits EL Arbouw, Kris LL Movig, Cees Neef, Henk-Jan Guchelaar, Toine CG Egberts. (Netherlands)
39 Impact of Variation in Interviewer Skill-Sets and Work Organization on Odds Ratios in an Interview Based Case-Control Study [320]
  Kerstin J Blomgren, Anders Sundstrom, Gunnar Steineck, Bengt-Erik Wiholm. (Sweden)

40 Evaluating the Impact of the American Academy of Pediatrics (AAP) and U.S. Public Health Service (USPHS) 1999 Joint Recommendation to Temporarily Delay Newborn Hepatitis B Vaccination Due to Thimerosal Content, Using Automated Data [321]
  Soju Chang, Elizabeth Begier, Stephanie D Schecch, Patricia Venus, Deborah Shatin, M Miles Braun, Robert Ball. (United States)

41 Aspirin and Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: Acute Brain Bleeding Analysis Study [322]
  Nam-Kyong Choi, Seung-Mi Lee, Byung-Woo Yoon, Byung-Joo Park. (Korea)

42 Weight Gain and Diabetes as a Side Effect of Psychiatric Medications [323]
  Norbert Dahmen, Andreas Horvath, Eveline Jaquenoud, Renate Grohmann. (Germany)

43 Risk of Osteoporosis/Osteopenia among Women with Breast Cancer Receiving Anti-Cancer Therapy (ACT) [324]
  Simone Peart Boyce, Mei Sheng Duh, Monika Raut, Jane Bradman, Edith A Perez, Betty A Mincey, Maryna Marynchenko, Monika Raut, Jane Bradman, Edith A Perez, Betty A Mincey, Maryna Marynchenko. (United States)

44 Matched Retrospective Cohort Study of Breast Cancer Incidence among Initiators of Racemc Zopiclone, Temazepam, and Zolpidem in the General Practice Research Database [325]
  P Mona Eng, Najat Ziyadeh, Beth L Nordstrom, Judy Caron, David Amato, John D Seeger. (United States)

45 Mortality and Vascular Events in Patients with Thyroid Dysfunction [326]
  Robert WV Flynn, Thomas M MacDonald, Roland T Jung, Andrew D Morris, Graham P Leese. (United Kingdom)

46 Indications, Efficacy and Tolerance of Cardiovascular Drugs at the End of Life [328]
  Robert J Glyn, Sebastian Schneeweiss, Til Stummer, Philip S Wang, Jerry Avorn. (United States)

47 Changes in Use of Cardiovascular Drugs

48 Cardiovascular Risk Factors at Baseline in Users of Coxibs Compared to Users of NSAIDs [329]
  Romy B de Jong, Nancy S Breekveldt-Postma, Wim G Goettsch, Ron MC Herings. (Netherlands)

49 Incidence of Malignant Neoplasm in Growth Hormone Deficient (GHD) Children Treated with Recombinant Growth Hormone (GH).
  KIGS Registry [330]
  Lia P Gutierrez, Andrew R Maguire, Anders F Mattsson, Patrick Wilton, On Behalf of the KIGS International Board. (Spain)

50 Psychotropic Drug Use Patterns in Youths with Anticonvulsants Therapy: A Study from the Netherlands [331]
  Yingfen Hsia, Paul van den Berg, Corinne S de Vries, Lokkie de Jong-van den Berg, Hilde Tobi. (Netherlands)

51 Galactorrhoea and Antipsychotic Medication: Data from the AMSP Project [332]
  Stefan Kropp, Eveline Jaquenoud Sirot, Andreas Horvath, Renate Grohmann. (Switzerland)

  Rachna Kasliwal, Lynda Wilton, Saad Shakir. (United Kingdom)

53 Inappropriate Drug Use in the Very Old – Temporal Trends [334]
  Inga Klarin, Johan Fastbom, Anders Wimo. (Sweden)

54 Macrolide Antibiotics during Pregnancy in Relation to Pyloric Stenosis [335]
  Yoonsook Lee. (United States)

55 Barriers to the Use of Adjuvant Chemotherapy in Stage III Colorectal Cancer [336]
  Samuel M Lesko, Trudy Coleman. (United States)

56 Demographic, Environmental, and Genetic Predictors of Metabolic Side Effects of Hydroxyurea Treatment in Hypertensive Subjects [337]
  Anke H Maitland-van der Zee, Stephen T Turner, Gary L Schwartz, Arlene B Chapman, Olaf H Klungel, Eric Boerwinkle. (Netherlands)

57 Abstract Withdrawn [338]

58 Abstract Withdrawn [339]

59 HIV-Infected Patients Presenting Adverse Effects (AE) Associated with Highly Active Antiretroviral Therapy (HAART): A Survey over an 18-Month Period [340]
  Aurelie Molia, Fabien Vitry, Christophe Strady, Isabelle Beguinot, Jean-Luc Berger, Anne Waldner, Christine Rouger, Thierry Tenreque. (France)

60 Use of Hormone Replacement Therapy and Risk of Non-Hodgkin Lymphoma [341]
  Mette Nøgaard, Aslak H Poulsen, Henrik Gregersen, Søren Friis, Marianne Ewertz, Hans E Johnsen, Henrik T Sørensen. (Denmark)

61 The Impact of Compliance with Statin on Coronary Artery Disease (CAD) Rate for Primary Prevention [342]
  Marie Hélène Bouchard, Alice Dragomir, Sylvie Perreault. (Canada)

62 Self-Reported Medication Adherence in a Population-Based Sample of Young African Americans and Whites: The CAR-DIA Study [343]
  Maribel Salas, O Dale Williams, John Blan, Pamela J Schreiner, Lucia Juarez, Yongjin Kim, Sharina D Person, Catarina Kiefe. (United States)

63 Abstract Withdrawn [344]

64 Prescription of Drugs during Pregnancy – What Is Going on in Russia? [345]
  Leonid S Stratchounski, Elena A Strizhenok. (Russian Federation)

65 Determinants of Switching between Two Drugs [346]
  Hani M Tamim, Jacques LeLorier. (Canada)

66 Abstract Withdrawn[347]

67 Rates of Serious Vascular Events among Patients Dispensed Type 2 Antidiabetic Medications in the U.S. and U.K. [348]
  Priscilla Velentgas, J Alexander Cole, Laurie Costa, Najat Ziyadeh, Kathleen Shea, John D Seeger, Alexander M Walker. (United States)

68 No Increase of Sudden Unexpected Deaths Following Immunization with Infanrix™ 4- and 5-valent Combination Vaccines [349]
  Thomas Verstraeten, Corinne Pierfitte, Thomas Breuer. (Belgium)

69 Compliance and Outcomes amongst Patients Being Treated for Both Hypertension and Raised Lipid [350]
  Li Wei, Thomas M MacDonald. (United Kingdom)
70 Maternal Asthma and Risk of Hypoglycemia [351]
Henrik Toft Sørensen, Lars Pedersen, Mette Nørgaard, Pia Wogelius, Kenneth J Rothman. (Denmark)

71 Antipsychotic-Induced Voluntary Movement Disorders: A Four-Year Inpatients Survey in Taiwan [352]
Shu-Yu Yang, Yea-Huei Kao Yang, Yi-Hsin Yang, Mian-Yoon Chong. (Taiwan)

72 Quality of Life Improvements with Olopitant Nasal Spray Treatment of Seasonal Allergic Rhinitis: Pooled Analysis of Two Randomized Controlled Trials [353]
Carol J Fairchild, Michael G Wall, Michael Brubaker, Margaret Drake. (United States)

73 The Validity of Using Pharmacy Records for Assessing the Retention Time of Drug Therapy [354]
Pieter D Knoester, Mirjam Heins, Yechiel A Hekster, Toine CG Egberts. (Netherlands)

74 Disability Measures in Stroke: Score Conversion between the Barthel Index and the Motor Component of Functional Independence Measure for Practitioner [355]
Sooyeon Kwon, Pamela W Duncan. (United States)

75 A Simulation Program for Epidemiologists, by Epidemiologists [356]
Ulla B Campbell*, Nicolle M Gatto*, Susan E Hodge. (United States)

76 Estimation of Hazard Functions for Adverse Events of Anti-Cancer Drug TS-1-Application of a Mixed Log-Logistic Model for Interval Censored Data- [357]
Akira Fukushima, Wataru Kashiwagi, Masaki Sano, Chikuma Hamada, Isao Yoshimura. (Japan)

77 Abstract Withdrawn [358]

78 Validation of Thai Community Hospital Databases for Health Policy Evaluations on Hospital Drug Utilization [359]
Penkarn Kanjanarat, Amit T Winterstein, Earlene Lipowski, Abraham G Hartzema, Martin Backstrom, Elisabet Ekman. (Sweden)

79 Consistency of Signal Detection Measures with Effect Measures in Epidemiology [360]
Tetsushi Komori, Takashi Ohmori, Tosiya Sato. (Japan)

80 Measuring Change in Drug Utilization [361]
John A Mandyk, Judith M Mackson, Fiona E Horn, Sonia E Wutzke, Lynn M Weekees. (Australia)

81 Assessing the Costs of Hepatitis A Food Related Interventions: Methodological Challenges [362]
Andrea C Trico, Ba’ D Pham, Bernard Duval, Vladimir Gilca, David Moher. (Canada)

82 Discontinuation of Aspirin, Warfarin and Clopidogrel, and Stroke Recurrence in Medicaid Patients [363]
Fadia T Shaya, Antoine C El Khoury, Hugh Fatodu, Matthew R Weir. (United States)

83 Time to Maximum Reporting Rate (TMR) and Time to Reversal of Reporting Rate (T3R) Are Useful in Post Marketing Signal Detection [364]
Swapu Banerjee, Bharat Thakrar. (United Kingdom)

84 A Study of the Quality of Information Provided in Serious Adverse Event Reports in Cancer Clinical Trials [365]
Jennifer Watts, Brenda Kowaleski, Andrew Arnold. (Canada)

85 Nurses as Reporters of Adverse Drug Reactions. A Link between the Health Care System and Regional Centres of Pharmacovigilance [366]
Martin Backstrom, Elisabet Ekman. (Sweden)

86 Meta-Analysis of Effect of Integrated Traditional Chinese Medicine and Western Medicine on SARS Treatments [367]
Yan Chen, Jeff J Guo. (United States)

87 Parents Report on Stimulant Treatment in the Netherlands: Initiation and Follow-Up Care [368]
Adriane Faber, Luuk J Kalverdijk, Jacqueline G Hugtenburg, Ruud B Minderaa, Lolijke TW de Jong-van den Berg, Hilde Tobi. (Netherlands)

88 How Is Non-Prescription Emergency Oral Contraception Being Used in Portugal? [369]
José P Guerreiro, Maria J Branco, Baltazar Nunes, Vera Gouveia. (Portugal)

89 Under-Reporting of Adverse Drug Reactions: A Systematic Review [370]
Lorna Hazell, Saad AW Shakir. (United Kingdom)

90 Hepatic Safety of Pegvisomant: An Example of Effective Lifecycle Risk Management Strategy [371]
Douglas E Kargman, Ferdinando E Vegni. (United States)

91 Decrease in Health Care Resource Utilization (HCRU) by Patients Started on Olanzapine for Treatment of Bipolar Affective Disorder (BPD) Using Régie De L’assurance Maladie Du Québec (Ramq) Administrative Databases [372]
Oiddle Sheehy, Deborah A Marshall, Nicole Brazier, Stuart MacLeod, Jacques LeLorier. (Canada)

92 Reduced Pulmonary Function in Subjects with Diabetes Mellitus [373]
Mark Ma, Indiana Strombom, Jeffrey Fergusson, Frank Delisle, Kenneth Hornbuckle. (United States)

93 Unique Clinical Trial Design To Assess the Efficacy of a Drug for Erectile Dysfunction in Various Populations [374]
Craig Donatucci, Irwin Goldstein, Geoffrey Sklar, Fanni Natanegara, Ann Cameron, David G Wong, Sanjeev Ahuja. (United States)

94 Cost-Effectiveness Analysis of Treatment Strategies for Heparin-Induced Thrombocytopenia [375]
Amanda R Patrick, Jerry Avorn, Wolfgang C Winkel, Michael A Fischer. (United States)

95 Epidemiological Research & Canadian Health Databases - A Systematic Review [376]
Andrea C Trico, Ba’ D Pham, Nigel SB Rawson, Reid C Robson. (Canada)

96 Prevalence and Treatment of Hypertensive Patients with Multiple Concomitant Cardiovascular Risk Factors in the Netherlands [377]
Miriam CJM Sturkenboom, Jeane P Dieleman, Gino Picelli, Essy Mozaffari, Marjolein Pompe, Johan van der Lei. (Netherlands)

97 Rates and Characteristics of Suicide Attempt Cases among Users of Antidepressants in Managed Care: A Seven-Year Case Series, 1997-2003 [378]
Robert J Valuck, Anne M Libby, Richard R Allen. (United States)